What does Okeiro do?
Okeiro specializes in precision medicine for transplantation and advanced chronic diseases. The company has developed an AI-driven clinical decision support platform centered on the clinically validated iBox algorithm, which helps predict post-transplant complications and improve diagnostic precision.
How much did they raise?
The funding round raised €10m, with the investment led by Alven, Forepont Capital Partners, and Red River West. Although the round type is classified as series_unknown, the significant capital infusion underscores strong investor confidence in the company's approach to revolutionizing patient care.
What are their plans for the money?
Okeiro intends to use the funds to accelerate its deployment across France and internationally while further developing new AI tools. This expansion is expected to enhance the precision of diagnostics, improve therapeutic recommendations, and streamline clinical research for chronic disease and transplant patients, potentially transforming patient monitoring and treatment protocols.
What have they achieved so far?
The company’s platform is already in use at transplant centers across France and has achieved national reimbursement status through the French National Health Insurance. Additionally, its ongoing randomized clinical trial across 16 hospital centers in six countries is showing promising interim results, further validating the technology’s clinical and economic value.
